The DOI matches its Crossref record; 232 of the 232 references it cites were found in a registry or an index.
Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer
Abstract
Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC is characterized with unique tumor microenvironment (TME), which differs from other subtypes. TME is associated with induction of proliferation, angiogenesis, inhibition of apoptosis and immune system suppression, and drug resistance. Exosomes are promising nanovesicles, which orchestrate the TME by communicating with different cells within TME. The components of TME including transformed ECM, soluble factors, immune suppressive cells, epigenetic modifications and re-programmed fibroblasts together hamper antitumor response and helps progression and metastasis of TNBCs. Therefore, TME could be a therapeutic target of TNBC. The current review presents latest updates on the role of exosomes in modulation of TME, approaches for targeting TME and combination of immune checkpoint inhibitors and target chemotherapeutics. Finally, we also discussed various phytochemicals that alter genetic, transcriptomic and proteomic profiles of TME along with current challenges and future implications. Thus, as TME is associated with the hallmarks of TNBC, the understanding of the impact of different components can improve the clinical benefits of TNBC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–232 of 232
Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy
Hope, H. C., & Salmond, R. J. (2019) · European Journal of Immunology · doi:10.1002/eji.201848058 · Cited by 38
Clark, D. P. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21951 · Cited by 37
Li, M., Xing, S., ZHANG, H., Shang, S., Li, X., REN, B., Gaiyun, L., CHANG, X., Li, Y., & Li, W. (2016) · Oncology Reports · doi:10.3892/or.2016.4547 · Cited by 36
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.005 · Cited by 36
Kang, N., Choi, S. Y., Kim, B. N., Yeo, C. D., Park, C. K., Kim, Y. K., Kim, T. J., Lee, S., Lee, S. H., Park, J. Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5360-7 · Cited by 36
Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
Concha‐Benavente, F., & Ferris, R. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00332 · Cited by 35
In Vivo Imaging of Pro- and Antitumoral Cellular Components of the Tumor Microenvironment
Helfen, A., Roth, J., Ng, T., & Eisenblätter, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198952 · Cited by 35
Jiang, F., Li, Y., Si, L., Zhang, Z., & Li, Z. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-018-09458-0 · Cited by 34
The mazy case of Notch and immunoregulatory cells
Grazioli, P., Felli, M. P., Screpanti, I., & Campese, A. F. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.1vmr1216-505r · Cited by 33
Cowherd, S., Miller, L. D., Melin, S. A., Akman, S. A., Isom, S. P., Cole, J., Pullikuth, A., & Lawrence, J. A. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1026481 · Cited by 32
IFN-γ and tumor gangliosides: Implications for the tumor microenvironment
Dillinger, B., Ahmadi-Erber, S. M., Lau, M., Hölzl, M. A., Erhart, F., Juergens, B., Fuchs, D., Heitger, A., Ladisch, S., & Dohnal, A. M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.014 · Cited by 32
Smits, B. M. G., Sharma, D., Samuelson, D. J., Woditschka, S., Mau, B., Haag, J. D., & Gould, M. N. (2011) · Breast Cancer Research · doi:10.1186/bcr2933 · Cited by 31
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P. S., Combs, S. E., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4264 · Cited by 31
Zhou, K., Ji, L., Yin, X., Han, X., Li, L., & Ma, B. (2019) · Biophysical Chemistry · doi:10.1016/j.bpc.2019.106213 · Cited by 31
CXM: A New Tool for Mapping Breast Cancer Risk in the Tumor Microenvironment
Flister, M. J., Endres, B. T., Rudemiller, N. P., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3212 · Cited by 27
Characterization of a selective CaMKII peptide inhibitor
Gomez-Monterrey, I. M., Sala, M., Rusciano, M. R., Monaco, S., Maione, A. S., Iaccarino, G., Tortorella, P., D’Ursi, A. M., Scrima, M., Carotenuto, A., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.053 · Cited by 26
Vadde, R., Radhakrishnan, S., Kurundu, H. E. K., Reddivari, L., & Vanamala, J. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.06.007 · Cited by 26
Genetic Modifiers of the Breast Tumor Microenvironment
Flister, M. J., & Bergom, C. R. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.04.003 · Cited by 26
MicroRNAs and Their Impact on Breast Cancer, the Tumor Microenvironment, and Disparities
Knowell, A. E., LaRue, A. C., & Findlay, V. J. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.08.003 · Cited by 25
Xu, X., Powell, D. W., Lambring, C. J., Puckett, A. H., Deschenes, L., Prough, R. A., Poeschla, E. M., & Samuelson, D. J. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21977 · Cited by 24
HIF-2α as a prognostic marker for breast cancer progression and patient survival
Wang, H. X., Qin, C., Han, F. Y., Wang, X. H., & Li, N. (2014) · Genetics and Molecular Research · doi:10.4238/2014.january.22.6 · Cited by 22
Jagtap, J. M. M., Sharma, G., Parchur, A. K., Gogineni, V. R., Bergom, C. R., White, S. B., Flister, M. J., & Joshi, A. (2018) · Biomedical Optics Express · doi:10.1364/boe.9.000543 · Cited by 20
Zhang, S., Hu, B., Lv, X., Chen, S., Liu, W., & Shao, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00390 · Cited by 20
Immunoscoring breast cancer: TILs remember what they target
Curigliano, G., & Perez, E. A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu227 · Cited by 18
Bhattacharya, S., Khanam, J., Sarkar, P., & Pal, T. K. (2019) · RSC Advances · doi:10.1039/c8ra08924h · Cited by 18
Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer
Kim, H., Samuel, S. L., Zhai, G., Rana, S., Taylor, M., Umphrey, H. R., Oelschlager, D. K., Buchsbaum, D. J., & Zinn, K. R. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29183 · Cited by 17
Düx, A., & Démant, P. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910400315 · Cited by 15
2′-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells
Nagaprashantha, L. D., Singhal, J., Chikara, S., Gugiu, G. B., Horne, D. A., Awasthi, S., Salgia, R., & Singhal, S. S. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.09.005 · Cited by 13
Li, M., Li, X., Zhuang, Y., Wang, Y., Burow, M. E., Collins‐Burow, B. M., Xue, M., Song, C., & Shan, B. (2016) · Oncotarget · doi:10.18632/oncotarget.10491 · Cited by 12
CoREST1 Promotes Tumor Formation and Tumor Stroma Interactions in a Mouse Model of Breast Cancer
Mazumdar, S., Arendt, L. M., Phillips, S. M., Sedic, M., Kuperwasser, C., & Gill, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121281 · Cited by 10
Lee, S., Diamond, M. A., Chadderton, A. R., Liu, H., Volgina, A., Roman, V. D., Weber, M., He, C., Stewart, R., Hertel, D., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-3929 · Cited by 8
[Role of PD-1/PD-L1 in microenvironment of breast cancer].
Ji, P., Gong, Y., & Hu, X. (2019) · PubMed · doi:10.3760/cma.j.issn.0253-3766.2019.06.001 · Cited by 1
Cited by
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Almansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
Liu, R., Wang, R., Zhao, M., Liu, Y., Zhu, X., Wu, X., Du, S., Gu, Z., & Du, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101997 · Cited by 23
Advances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer
Yousafzai, N. A., El Khalki, L., Wang, W., Szpendyk, J., & Sossey-Alaoui, K. (2024) · Cancers · doi:10.3390/cancers16050883 · Cited by 20
Metadata
- Authors
- Deepak, K. G. K., Vempati, R., Nagaraju, G. P., Dasari, V. R., S., N., Rao, D. N., & Malla, R. R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 153
- Pages
- 104683
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W3005410912
- Cited by
- 614
- References
- 232
- FWCI
- 21.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.